Gut

human & experimental toxicology

arab journal of gastroenterology : the official publication of the pan-arab association of gastroenterology

[1] Effects of infliximab against carbon tetrachloride-induced intestinal injury via lipid peroxidation and apoptosis.

[2] Evaluating the effect of infliximab on the healing of left colonic anastomosis in the presence of intra-abdominal sepsis.

[3] comparative efficacy and safety of infliximab biosimilar (bcd-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase i and phase iii clinical studies)

[4] neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases

[5] loss of response to long-term infliximab therapy in children with crohn’s disease

[6] pyoderma gangrenosum in pregnancy successfully treated with infliximab and prednisone

[7] effect of infliximab dose increase in rheumatoid arthritis at different trough concentrations: a cohort study in clinical practice conditions

[8] Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.

[9] Effects of infliximab against carbon tetrachloride-induced intestinal injury via lipid peroxidation and apoptosis.

[10] Evaluating the effect of infliximab on the healing of left colonic anastomosis in the presence of intra-abdominal sepsis.

[11] A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

[12] Infliximab Does Not Affect Dendritic Cells' Mediated Lymphoproliferative Response to Histoplasma Capsulatum

[13] comparative efficacy and safety of infliximab biosimilar (bcd-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase i and phase iii clinical studies)

[14] long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis

[15] cause for controversy? infliximab in the treatment of ulcerative colitis: an update

[16] listeria meningitis complicating infliximab treatment for crohn’s disease

[17] loss of response to long-term infliximab therapy in children with crohn’s disease

[18] infliximab induces increase in triglyceride levels in psoriatic arthritis patients

[19] nÍveis adequados de infliximabe associaram‐se À melhoria na qualidade de vida de pacientes com doenÇa inflamatÓria intestinal: dados de vida real

[20] meningitis por listeria como complicación del tratamiento con infliximab en paciente con enfermedad de crohn listeria meningitis as complication of treatment with infliximab in a patient with crohn's disease

[21] crohn's disease associated with sweet's syndrome and sjögren's syndrome treated with infliximab

[22] stabilization of bilateral progressive rheumatoid corneal melt with infliximab

[23] pyoderma gangrenosum in pregnancy successfully treated with infliximab and prednisone

[24] effect of infliximab dose increase in rheumatoid arthritis at different trough concentrations: a cohort study in clinical practice conditions

[25] quality of life in children with juvenile rheumatoid arthritis treated with infliximab

[26] computed tomography imaging findings in erythrodermic psoriasis treated with infliximab: a case report

[27] successful discontinuation of infliximab in a refractory case of vasculo-behçet disease

[28] effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in crohn's disease

[29] episcleritis related to drug-induced lupus erythematosus following infliximab therapy: a case report

[30] canadian association of gastroenterology clinical practice guidelines: the use of infliximab in crohn's disease

[31] Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab